Polish medtech startup ONGENO has a therapy developed by Dr. Wojciech Orlowski, M.D., which has been proven in the first phase of the experiment to lead to improved sclerosis patient health, reduced disability, and lack of disease progression in the long term.
ONGENO has raised €3.5M across 1 funding round, most recently a round in Jan 2025. Based in Warsaw, Poland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-21 | Other | €3.5M |
| — |
| View deal → |
